Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Recruiting NCT05614180

Chronic Total Occlusive Lesions CMR Study

Conditions: Chronic Total Occlusion, Image, Revascularization

Sex: All
Ages: 18 Years – 80 Years
Enrollment: 400
Sponsor: Lin Zhao

Location: China

Summary

This registry will include consecutive patients presenting with at least one chronic total occlusion on coronary angiogram who will be treated by percutaneous coronary intervention in our center. All patients will undergo a non-invasive assessment for myocardial ischemia/viability using cardiac magnetic resonance (CMR) prior to revascularization therapy. Follow up CMR will be repeated in all participants after three months and one year. Additionally, clinical outcomes and quality of life will be evaluated at baseline and at follow-up. Primary objective of this study is to investigate the the reduction in ischemia (as evaluated by follow-up CMR) and the severity of angina according to clinical evaluation (including Seattle Angina Questionnaires [SAQ], Canadian Class Score[CCS] and 6-mins walking test).

Eligibility Criteria

Inclusion Criteria:Age > 18 yearsPresence of at least one untreated CTO at basal angiography (defined as a total occlusion in any major coronary vessel or relevant side branches [reference vessel diameter ≥2.5mm or as judged by two independent interventional cardiologists], with TIMI 0 in the distal segment and at least 3 months oldPatient has a clinical indication to perform CTO PCIWilling to participate and able to understand, read and sign the informed consent document.Exclusion Criteria:CMR contraindicationsContraindications to adenosine or dobutamineSevere chronic kidney disease (estimated Glomerular Filtration Rate [eGFR] <60 mL/min/1.73m2 or serum creatinine level >2.5 mg/dL)

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05614180). StuddyBuddy aggregates publicly available trial information.